Qrons (QRON) 10-K 31 Mar 23 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2023	Jun. 30, 2022
Cover [Abstract]
Entity Registrant Name	QRONS INC.
Entity Central Index Key	0001689084
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		13,439,789
Entity Public Float			$ 1,327,916
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-55800
Entity Incorporation State Country Code	WY
Entity Tax Identification Number	81-3623646
Entity Interactive Data Current	Yes
Icfr Auditor Attestation Flag	false
Entity Address Address Line 1	28-10 Jackson Avenue #26N
Entity Address City Or Town	Long Island City
Entity Address State Or Province	NY
Entity Address Postal Zip Code	11101
City Area Code	212
Local Phone Number	945-2080
Security 12g Title	Common Stock, $0.0001 par value
Auditor Firm Id	6117
Auditor Name	Heaton & Company, PLLC
Auditor Location	Farmington, Utah

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 3,069	$ 35,065
Total current assets	3,069	35,065
TOTAL ASSETS	3,069	35,065
Current liabilities
Accounts payable and accrued liabilities	128,285	90,976
Accounts payable and accrued liabilities - related party	42,671	38,192
Demand loans, related party	85,873	50,000
Unsecured short-term advances	100,000	100,000
Convertible notes - related party	0	25,000
Convertible notes, net of debt discount	208,247	141,685
Derivative liabilities	358,775	405,957
Total current liabilities	1,282,351	1,137,810
Total liabilities	1,282,351	1,137,810
Stockholders' deficit
Series A Preferred stock: $0.001 par value; 10,000 shares authorized; 2,000 shares issued and outstanding	2	2
Common stock, $0.0001 par value: 100,000,000 shares authorized; 13,439,789 and 13,289,789 shares issued and outstanding as of December 31, 2022 and 2021, respectively	1,344	1,329
Additional paid-in capital	8,254,316	7,697,351
Accumulated deficit	(9,534,944)	(8,801,427)
Total stockholders' deficit	(1,279,282)	(1,102,745)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 3,069	$ 35,065

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Condensed Balance Sheets
Series A Preferred Shares, par value	$ 0.001	$ 0.001
Series A Preferred Shares, authorized	10,000	10,000
Series A Preferred Shares, shares issued	2,000	2,000
Series A Preferred Shares, shares outstanding	2,000	2,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,439,789	13,289,789
Common stock, shares outstanding	13,439,789	13,289,789

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Condensed Statements of Operations
Net sales	$ 0	$ 0
Operating expenses:
Research and development expenses	194,406	258,297
Professional fees	70,199	48,332
General and administrative expenses	365,024	495,323
Total operating expenses	629,629	801,952
Loss from operations	(629,629)	(801,952)
Other income (expense)
Interest expense	(135,654)	(208,892)
Change in derivative liabilities	31,766	(57,140)
Total other income (expense)	(103,888)	(266,032)
Net loss	$ (733,517)	$ (1,067,984)
Net loss per common shares (basic and diluted)	$ (0.06)	$ (0.08)
Weighted average shares outstanding (basic and diluted)	13,299,652	13,289,789

Condensed Statement of Changes

Condensed Statement of Changes in Stockholders Equity Deficit - USD ($)	Total	Common Stock	Preferred Stock Series A [Member]	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2020		13,289,789	2,000
Balance, amount at Dec. 31, 2020	$ (694,316)	$ 1,329	$ 2	$ 7,037,796	$ (7,733,443)
Stock options granted to officers	435,570			435,570
Stock options granted to non-employees as research and development costs	223,985			223,985
Net loss for the year	(1,067,984)				(1,067,984)
Balance, shares at Dec. 31, 2021		13,289,789	2,000
Balance, amount at Dec. 31, 2021	(1,102,745)	$ 1,329	$ 2	7,697,351	(8,801,427)
Stock options granted to officers	320,420			320,420
Stock options granted to non-employees as research and development costs	160,210			160,210
Net loss for the year	(733,517)				(733,517)
Issuance of common stock to noteholder, shares		150,000
Issuance of common stock to noteholder, amount	76,350	$ 15		76,335
Balance, shares at Dec. 31, 2022		13,439,789	2,000
Balance, amount at Dec. 31, 2022	$ (1,279,282)	$ 1,344	$ 2	$ 8,254,316	$ (9,534,944)

Condensed Statement of Cash Flo

Condensed Statement of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows From Operating Activities
Net loss	$ 733,517	$ 1,067,984
Adjustments to reconcile net loss to net cash used by operating activities:
Stock options issued for research and development expense	160,210	223,985
Stock options granted for officer compensation	320,420	435,570
Non cash interest expense	62,100	94,332
Accretion of debt discount	56,196	98,049
Change in derivative liabilities	(31,766)	57,140
Changes in operating assets and liabilities:
Increase accounts payable and accrued liabilities	46,509	41,917
(Decrease) increase accounts payable and accrued liabilities - related party	15,352	(5,576)
Net cash used by operating activities	(104,496)	(122,567)
Cash Flows From Investing Activities
Net cash provided from (used by) investing activities	0	0
Cash Flows From Financing Activities
Proceeds from convertible notes	0	100,000
Proceeds from related party advances	72,500	0
Net cash provided from financing activities	72,500	100,000
Decrease in cash and cash equivalents	(31,996)	(22,567)
Cash at beginning of year	35,065	57,632
Cash at end of period	3,069	35,065
SUPPLEMENTAL DISCLOSURES
Interest paid	0	0
Income taxes paid	0	0
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Common stock issued under Note amended	76,350	0
Debt discount from amended convertible note	24,634	0
Accrued interest payable modified to Note amended	9,200	0
Convertible notes - related party modified to 6% promissory note	25,000	0
Accrued interest payable - related party modified to 6% promissory note	10,873	0
Derivative liability associated with debt discount	0	51,009
Derivative liability associated with warrants	$ 15,416	$ 143,323

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2022
Description of Business and Basis of Presentation
Description of Business and Basis of Presentation	Note 1 – Description of Business and Basis of Presentation Organization and Nature of Business: Qrons Inc. (“Qrons” or the “Company”) was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. and changed its name to Qrons Inc., effective August 8, 2017. The Company’s common stock was approved by the Financial Industry Regulatory Authority (“FINRA”) for quotation on the OTC pink sheets under the symbol “BLMB” as of July 3, 2017. FINRA announced the Company’s name change to Qrons Inc. on August 9, 2017. The new name and symbol change to “QRON” for the OTC Market was effective August 10, 2017. The Company’s common stock commenced trading on the OTCQB Venture Market on August 12, 2019. The Company is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal diseases, which are an enormous social and economic burden on society. The Company seeks to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. The Company’s search is currently focused on researchers based in Israel, a country which is world-renowned for biotech innovations and where its President is located and where its research to date has been conducted. The Company’s principal executive office is located at 28-10 Jackson Avenue, Long Island City, #26N, New York 11101.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Financial Statements: Fiscal year end: Use of Estimates: Cash Equivalents: Research and Development Costs: Research and Development Advertising and Marketing Costs: Related Parties: Basic and Diluted Loss Per Share Earnings Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The table below reflects the potentially dilutive securities outstanding during each reporting period: December 31, 2022 December 31, 2021 Research warrants at 3% of issued and outstanding shares 403,194 398,694 Convertible notes 460,000 564,719 Series A preferred shares 700 700 Stock options vested 4,328,332 4,098,332 Stock purchase warrants 295,000 295,000 Total 5,487,226 5,357,445 Recently Issued Accounting Pronouncements Not Yet Adopted: In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2022
Going Concern
Going Concern	Note 3 – Going Concern The Company has experienced net losses to date and has not generated revenues from operations. While the Company raised proceeds of $100,000 during the year ended December 31, 2021 through the issuance of a convertible promissory note, and a further $72,500 in unsecured advances from related parties in the current year ended December 31, 2022, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the coming year of 2023. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing, and continued support from its officers and directors. There can be no assurance that financing, whether debt or equity, will be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. In addition, if the Company is unable to obtain adequate financing due to the continued effect of COVID-19 on the capital markets, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty. Covid-19 Pandemic The COVID-19 pandemic has had an adverse impact on the research and development of our product candidates. Research facilities at Dartmouth were subject to closures as well as laboratories at Ariel in Israel during fiscal 2020. This resulted in our discontinuing our research at these universities and was part of our decision to adjust our research to be collaborative and to seek aligning with third parties to advance our expanded goals. COVID-19 also caused significant disruptions to the global financial markets, which severely impacted our ability to raise additional capital. We terminated our employees in April 2020 in an effort to conserve resources as we evaluated our business development efforts. We may be required to further reduce operations or cease operations if we are unable to finance our operations. We remain unable to predict with certainty the ongoing effects of the COVID-19 pandemic on future operations, as well as the actions of governments, and when and to what extent normal economic and operating conditions will return to pre-pandemic levels. Even as the COVID-19 pandemic has subsided, we continue to experience adverse impacts to our business, including delays on the successful raising of additional capital.

Convertible Note Related Party

Convertible Note Related Party and Derivative Liabilities	12 Months Ended
	Dec. 31, 2022
Convertible Note Related Party and Derivative Liabilities
Convertible Note Related Party and Derivative Liabilities	Note 4 – Convertible Note – Related Party and Derivative Liabilities On September 1, 2016, the Company entered into a convertible debenture agreement with Decagon LLC, doing business as CubeSquare, LLC (“CubeSquare”), of which the Company’s Chief Executive Officer is the managing partner and its President is a 25% owner of CubeSquare. The Company received proceeds of $10,000 during fiscal 2016 (“Note 1”). Note 1 bears interest at 8% per annum and was due on September 1, 2017. Interest accrues from September 1, 2016 and is payable on maturity. Interest is payable, at the lender’s option, in cash or common stock. Any portion of the loan and unpaid interest is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price of the greater of (i) $0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender. On September 29, 2017, the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018; on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019; on November 6, 2019, the Company further amended Note 1 to extend the maturity date to September 1, 2020; on October 30, 2020, the Company further amended Note 1 to extend the maturity date to September 1, 2021; and on October 7, 2021, the Company further amended Note 1 to extend the maturity date to September 1, 2022 under the same terms and conditions. On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and was due on September 27, 2018. Interest accrues from September 27, 2017 and is payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. On September 9, 2018, Note 2 was amended to extend the maturity date to September 27, 2019. On November 6, 2019, Note 2 was amended to extend the maturity date to September 27, 2020; on October 30, 2020 Note 2 was amended to extend the maturity date to September 27, 2021; and further on October 7, 2021 Note 2 was amended to extend the maturity date to September 27, 2022. On September 27, 2022 the Board and the noteholder agreed to cancel the two convertible notes and in full satisfaction of such outstanding debt to issue a new 6% non-convertible promissory note to CubeSquare in the principal amount of $35,873 (the “New Note”), representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022. The Company analyzed the amendment to Note 1 and Note 2 under ASC 815-10-15-83 and concluded that the conversion feature within these two convertible Notes meet the definition of a derivative. The Company estimated the fair value of the derivative at each report date using the Black-Scholes valuation model to value the derivative liability related to the variable conversion rate. There is no derivative liability associated with the New Note given the absence of a conversion feature. The carrying value of these convertible notes is as follows: December 31, 2022 December 31, 2021 Face value of certain convertible notes $ 25,000 $ 25,000 Convertible notes extinguish (25,000 ) - Carrying value $ - $ 25,000 For Years Ended December 31, 2022 2021 Interest on the convertible notes $ 1,424 $ 2,000 As of December 31, 2022 and 2021, the unpaid interest balance under Accounts payable and accrued liabilities – related party was $0 and $9,449, respectively. As a result of the application of ASC 815, the fair value of the derivative liability associated with the conversion feature is summarized as follows: Balance at December 31, 2020 $ 61,682 Change in fair value 11,417 Balance at December 31, 2021 73,099 Change in fair value (73,099 ) Balance at December 31, 2022 $ 0 The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of September 27, 2022 and December 31, 2021 and the commitment date: Commitment Date December 31, 2021 September 27, 2022 Expected dividends 0 0 0 Expected volatility 101%-103 % 181%-182 % 101.56 % Expected term 0.92 - 1 year 0.67 - 0.74 year 0.00 year Risk free interest rate 1.33 % 1.06 % 2.22 %

Convertible Note and Derivative

Convertible Note and Derivative Liabilities	12 Months Ended
	Dec. 31, 2022
Convertible Note and Derivative Liabilities
Convertible Note and Derivative Liabilities	Note 5 – Convertible Note and Derivative Liabilities (1) 8% Convertible notes with warrants issued in December 2019 and February 2020 In December 2019, we issued and sold in a private offering 8% convertible notes in the aggregate principal amount of $70,000. Such notes were due on December 31, 2021 and are convertible into shares of our common stock at a conversion price for each share of common stock equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) so long as lower than (a) or (b), such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00. The Company extended the maturity date to December 2022 and further extended the maturity date to December 2023 under the same terms and conditions. On February 19, 2020 we issued and sold in a private offering an 8% convertible note in the principal amount of $10,000. The note is due on February 19, 2022 and is convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; or (c) such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 10,000 shares of common stock at an exercise price of $1.00. The Company extended the maturity date to February 2022 and further extended the maturity date to February 2023 under the same terms and conditions. The carrying value of these convertible notes is as follows: December 31, 2022 December 31, 2021 Face value of certain convertible notes $ 80,000 $ 80,000 Less: unamortized discount - (541 ) Carrying value $ 80,000 $ 79,459 Interest expenses associated with the convertible notes are as follows: Years Ended December 31, 2022 2021 Amortization on debt discount $ 541 $ 35,823 Interest on the convertible notes 6,400 5,496 Total $ 6,941 $ 41,319 As of December 31, 2022 and 2021, the unpaid interest balance under Accounts payable and accrued liabilities was $19,269 and $12,869, respectively. The convertible notes qualify for derivative accounting and bifurcation under ASC 815. The derivative liability of the $80,000 convertible notes was calculated using the Black-Scholes pricing model to be $72,689. As a result of the application of ASC 815, as of December 31, 2022 and 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows: Balance at December 31, 2020 $ 92,803 Change in fair value 64,687 Balance at December 31, 2021 157,490 Change in fair value (100,457 ) Balance at December 31, 2022 $ 57,033 The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of December 31, 2022 and 2021 and the commitment date: Commitment Date December 31, 2021 December 31, 2022 Expected dividends 0 0 0 Expected volatility 154%-173 % 203%-301 % 194.20%-201.98 % Expected term 2.10 years 1.08 - 1.22 years 1.08 - 1.22 years Risk free interest rate 1.42 - 1.65 % 0.39 % 4.41 % (2) 8% Convertible note with warrants issued on June 15, 2021 On June 15, 2021, the Company entered into a note purchase agreement with Quick Capital, LLC (“Quick Capital”) pursuant to which the Company issued a twelve-month convertible promissory note in the principal amount of $115,000 for a $100,000 investment (the “Quick Note”), which included an original issuance discount of 10% and a $3,500 credit for legal and transaction costs. In connection with the Quick Note issuance, Quick Capital was also issued a five-year warrant (the “Quick Warrant”) to purchase up to an aggregate of 115,000 shares of the Company’s common stock at an exercise price of $1.00 per share (the “Quick Warrant Shares”) subject to adjustments for dilutive issuances at lower prices. The Quick Note is convertible into shares of common stock at a conversion price of $0.50 per share. If delivery of the conversion shares is not timely made, the Company is obligated to pay Quick Capital $2,000 for each day that the delivery is late as liquidated damages. The conversion price of the Quick Note will be reduced if the Company issues common stock or grants derivative securities for consideration at a price less than the conversion price to the amount of the consideration of such dilutive issuance. The Quick Note may not be prepaid. The Company is subject to significant cash penalties if the Company defaults on the Quick Note or in the event shares are not issued timely when a notice of conversion is provided. If an event of default occurs, the Quick Note will become immediately due and payable in an amount equal to 150% of the then outstanding principal amount of the Quick Note plus any interest or amounts owing to Quick Capital. The default provisions are based on the type of default and include a penalty of 50% of the principal plus accrued interest due (the “Default Sum”) and a parity value of the Default Sum based on the effective conversion of the Quick Note on the date of payment of the default and the maximum stock value during the period between the default date and the payment date. The Note and accrued interest totaling $124,200 was not repaid on maturity, constituting an event of default increasing the repayment value of the note to an amount equal to 150% of the principal balance and accrued interest outstanding, or $186,300. On December 7, 2022, the Company and Quick Capital amended the Note to extend the maturity date thereof to June 15, 2023, and amended the Warrant maturity date to June 15, 2027. Further Quick Capital agreed to reduce the outstanding balance of the Note from $186,300 to $150,000 in consideration for the issuance of 150,000 shares of unregistered, restricted common stock valued at $76,350. Details of the valuation of the 150,000 shares of common stock are set out below: December 7, 2022: Note Payable, original face value $ 115,000 Accrued interest and default penalty on default 71,300 Convertible Note Payable, amended (150,000 ) Debt discount, day one, amended convertible note payable 24,436 Derivative Liability associated with warrants (15,416 ) Change in Fair Value 31,030 Fair value of Common stock issued $ 76,350 The unpaid balance of the Note continues to accrue interest at 8% per annum. The Company valued the embedded default derivative liability of the Quick Note and the Quick Warrant liability, including the full ratchet reset feature, using Monte Carlo models. The fair value of the Quick Note and Quick Warrant embedded default derivatives liability has been valued as of December 31, 2022. The carrying value of the Quick Note is as follows: December 31, 2022 December 31, 2021 Face value of Quick Note $ 150,000 $ 115,000 Less: unamortized discount (21,753 ) (52,774 ) Carrying value $ 128,247 $ 62,226 Interest expenses associated with the conversion feature is as follows: Years ended December 31, 2022 2021 Amortization of debt discount $ 55,655 $ 62,226 Default interest 62,100 - Day one loss associated with derivative liability - 79,332 Interest on the convertible notes 4,973 5,016 Total $ 122,728 $ 146,574 As of December 31, 2022 and 2021, the unpaid interest balance under Accounts payable and accrued liabilities was $789 and $5,016, respectively. As a result of the application of ASC 815 as of December 31, 2022 and 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows: Derivative liability associated with convertible note on commitment date $ 51,009 Derivative liability associated with warrants on commitment date 143,323 Change in fair value – convertible note (21,597 ) Change in fair value – warrants 2,633 Balance at December 31, 2021 175,368 Derivative liability associated with Note amendment – warrants (15,416 ) Change in fair value – convertible note (5,161 ) Change in fair value – warrants 146,951 Balance at December 31, 2022 $ 301,742 The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of December 31, 2022 and 2021 and the commitment date: Convertible note: Commitment Date December 31, 2021 December 31, 2022 Expected dividends 0 0 0 Expected volatility 307.10 % 215.70 % 119.70 % Expected term 1 years 0.45 years 0.45 years Risk free interest rate 0.18 % 0.43 % 4.37 % Warrants: Commitment Date December 31, 2021 December 31, 2022 Expected dividends 0 0 0 Expected volatility 201.70 % 200.90 % 219.10 % Expected term 5 years 4.45 years 4.45 years Risk free interest rate 0.65 % 0.82 % 4.27 %

Unsecured Short-Term Advance fr

Unsecured Short-Term Advance from Third Party	12 Months Ended
	Dec. 31, 2022
Unsecured Short-Term Advance from Third Party
Term Advance from Third Party	Note 6 – Unsecured Short-Term Advance from Third Party On June 20, 2019, the Company received $100,000 from a third party in the form of an unsecured, demand, non-interest-bearing, short-term advance to meet its operating needs. The advance remains outstanding at December 31, 2022 and 2021.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions
Related Party Transactions	Note 7 – Related Party Transactions (1) Demand Loan from related party On May 1, 2019, the Company issued a promissory note (the “Note”) to CubeSquare in the principal amount of $50,000. The Company’s Chief Executive Officer is the managing partner and the Company’s President is a 25% owner of CubeSquare. The Note bears interest at the rate of 8% per annum and is due and payable by the Company upon demand from CubeSquare. The Company recorded interest expenses of $4,000 for the years ended December 31, 2022 and 2021. On September 27, 2022 the Board and the related party noteholder agreed to cancel two convertible notes issued to Cubesquare and in full satisfaction of such outstanding debt to issue a new 6% promissory note (Ref: Note 4) in the principal amount of $35,873, representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022. The Company recorded interest expenses of $560 in respect to the new note through December 31, 2022. As of December 31, 2022 and 2021, the unpaid interest balance under Accounts payable and accrued liabilities – related party in respect of the aforementioned notes was $15,234 and $10,674, respectively. (2) Advances from Related Parties During the year ended December 31, 2019, the Company received $135,000 from Jonah Meer, its Chief Executive Officer, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $70,000 from Jonah Meer. An additional $72,500 in advances was received from Mr. Meer during the year ended December 31, 2022. Mr. Meer is owed $277,500 and $205,000 in respect to these advances at December 31, 2022 and 2021, respectively. On August 20, 2019, the Company received $50,000 from Ido Merfeld, its President, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $21,000 from Ido Merfeld. There were no additional advances from Mr. Merfeld during the years ended December 31, 2022 and 2021. Mr. Merfeld is owed $71,000 in respect to these advances at December 31, 2022 and 2021. During the year ended December 31, 2020, the Company received $10,000 from CubeSquare in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs which amount is outstanding as of December 31, 2022 and 2021. (3) Others Jonah Meer, the Company’s Chief Executive Officer, made payments of $10,268 and $0 to various vendors during the year ended December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021, the Company repaid $900 and $11,575, respectively, of these advances leaving a balance payable to Mr. Meer of $26,268 at December 31, 2022 (December 31, 2021 - $16,900), which amount is reflected in accounts payable, related party. During the year ended December 31, 2019, Ido Merfeld, the Company’s President, made payments to various vendors in the aggregate amount of $1,169. The balance payable to Mr. Merfeld of $1,169 is reflected in accounts payable, related party as of December 31, 2022 and 2021.

Intellectual Property License A

Intellectual Property License Agreement and Sponsored Research Agreement	12 Months Ended
	Dec. 31, 2022
Intellectual Property License Agreement and Sponsored Research Agreement
Intellectual Property License Agreement and Sponsored Research Agreement	Note 8 – Intellectual Property License Agreement and Sponsored Research Agreement Dartmouth College – Intellectual Property License Agreement On October 2, 2019, the Company entered into an intellectual property license agreement (the “Intellectual Property License Agreement”) pursuant to which Dartmouth granted the Company an exclusive world-wide license under the patent application entitled “Mechanically Interlocked Molecules-based Materials for 3D Printing” in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services. The license grant includes the right of the Company to sublicense to third parties subject to the terms of the Agreement. The Agreement provided for: (i) a $25,000 license issue fee; (ii) an annual license maintenance fee of $25,000, until the first commercial sale of a licensed product or service; (iii) an earned royalty of 2% of net sales of licensed products and services by the Company or a sublicensee; (iv) 15% of consideration received by the Company under a sublicense; and (v) beginning in the first calendar year after the first commercial sale, an annual minimum royalty payment of $500,000, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter. The Company will also reimburse Dartmouth for all patent preparation, filing, maintenance and defense costs. Failure to timely make any payment due under the Agreement will result in interest charges to the Company of the lower of 10% per year or the maximum amount of interest allowable by applicable law. The Agreement may be terminated by Dartmouth if the Company is in material breach of the Agreement which is not cured after 30 days of notice thereof or if the Company becomes insolvent. Dartmouth may terminate the Agreement if the Company challenges a Dartmouth patent or does not terminate a sublicensee that challenges a Dartmouth patent, except in response to a valid court or governmental order. The Company may terminate the Agreement at any time upon six months written notice to Dartmouth. If the Company or any sublicensee or affiliate institutes or participates in a licensed patent challenge, the then current earned royalty rate for licensed products covered by Dartmouth patents will automatically be increased to three times the then current earned royalty rate. On March 23, 2021, the United States Patent and Trademark Office issued U.S. Patent No. 10,954,315 to the Trustees of Dartmouth College, which is directed to mechanically interlocked, molecules-based materials for 3-D printing. The patent’s inventors are Professor Chenfeng Ke, a member of the Company’s Scientific Advisory Board and Qianming Lin, Professor Ke’s assistant. The patent grant is the culmination of the Intellectual Property License Agreement between the Company and Dartmouth with respect to an exclusive world-wide license of intellectual property related to 3D printable materials in the fields of human and animal health. Dartmouth College – Intellectual Property License Agreement The Company expensed $25,000 as license fees during the years ended December 31, 2022 and 2021 with respect to such annual fee.

Stock Plan

Stock Plan	12 Months Ended
	Dec. 31, 2022
Stock Plan
Stock Plan	Note 9 – Stock Plan 2016 Stock Option and Stock Award On December 14, 2016, the Board adopted the Company’s 2016 Stock Option and Stock Award Plan (the “Plan”). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Board. The Company has reserved 10 million shares for issuance under the Plan. (a) Stock Options granted to Science Advisors and Business Advisors On February 10, 2020 under the Plan, the Company granted three-year options to purchase an aggregate of 50,000 shares of its common stock at an exercise price of $2.00 per share, to a Business Advisor. 25,000 of such shares subject to the option were immediately exercisable and expired on February 10, 2023, and 25,000 shares vest on February 10, 2021 and expire on February 10, 2024. On July 15, 2020, 25,000 unvested options were forfeited. In January 2021, 25,000 vested options were forfeited. (b) Stock Options granted to Employees: On December 10, 2018, the Board awarded an employee the following three-year stock options under the Plan: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, provided the employee is providing services to the Company at the time of exercise. On March 23, 2020, the Company accelerated the vesting provision to provide for the immediate vesting of such options. 33,333 of such shares subject to the option were forfeited unexercised on December 10, 2021. The remaining option expired on March 23, 2023. On December 10, 2019, the Board awarded an employee, the following three-year stock options under the Plan: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2021 at an exercise price of $2.00 per share, provided the employee is providing services to the Company at the time of exercise. On March 23, 2020, the Company accelerated the vesting provision to provide for the immediate vesting of such options. Such options expired on March 23, 2023. On December 10, 2020, under the Plan, the Board awarded an employee, an immediately exercisable three-year stock option to purchase 100,000 shares of the common stock of the Company at an exercise price of $2.00 per share. On December 22, 2021, under the Plan, the Board awarded an employee, an immediately exercisable three-year stock option to purchase 325,000 shares of the common stock of the Company at an exercise price of $2.00 per share. On December 22, 2022, under the Plan, the Board awarded an employee, an immediately exercisable three-year stock option to purchase 325,000 shares of the common stock of the Company at an exercise price of $2.00 per share. On April 16, 2022, a three-year stock option to purchase 10,000 shares of common stock of the Company granted to a Science Advisor expired unexercised. On July 1, 2022, a three-year stock option to purchase 33,334 shares of common stock of the Company granted to a Science Advisor expired unexercised. On August 15, 2022, a three-year stock option to purchase 6,666 shares of common stock of the Company granted to a Science Advisor expired unexercised. On November 15, 2022, a three-year stock option to purchase 28,332 shares of common stock of the Company granted to a Science Advisor expired unexercised. On December 17, 2022, a three-year stock option to purchase 66,668 shares of common stock of the Company granted to a Science Advisor expired unexercised. The following table is the recognized compensation in respect of the above stock option compensation ((a) and (b)) which amount has been allocated as below: Years ended December 31, 2023 2022 Research and development expenses $ 160,210 $ 223,985 As of December 31, 2022 and 2021, there was no unrecognized compensation remaining to be recognized in future periods. (c) Stock Options granted to Officers: On June 25, 2019, the Company appointed John N. Bonfiglio, PhD as its chief operating officer, effective July 1, 2019. As compensation, Dr. Bonfiglio was granted a three-year stock option to purchase 100,000 shares of common stock at an exercise price of $2.00 per share, 50,000 of which shares vested upon grant and 25,000 shares vested on each of July 1, 2020 and July 1, 2021, provided Dr. Bonfiglio was in the employ of the Company on such dates. Mr. Bonfiglio was terminated as chief operating officer as of November 30, 2019. Accordingly, all unvested stock options terminated on such date. In January 2021, 50,000 vested options were forfeited. On December 10, 2020, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share and are immediately exercisable. On December 22, 2021, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share and are immediately exercisable. On December 22, 2022, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share and are immediately exercisable. On December 4, 2022, a five-year stock option to purchase 600,000 shares of common stock of the Company granted to officers expired unexercised. The following table is the recognized compensation in respect of the above stock option compensation, which amounts have been allocated as general and administrative expenses: Years ended December 31, 2022 2021 General and administrative expenses $ 320,420 $ 435,570 The fair value of each option award referenced above is estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0 % Expected volatility 114.69-209.74 % Risk-free interest rate 0.39%-3.79 % Expected life (years) 3 - 5 Stock Price $ 0.38 - 2.80 Exercise Price $ 0.40 - 2.00 A summary of the activity for the Company’s stock options at December 31, 2022 and 2021, is as follows: December 31, 2022 December 31, 2021 Weighted Average Exercise Weighted Average Remaining Contractual Life Weighted Average Exercise Weighted Average Remaining Contractual Life Shares Price (in years) Shares Price (in years) Outstanding, beginning of period 4,098,332 $ 2 3.08 3,276,666 $ 1.98 3.28 Granted 975,000 2 - 975,000 $ 2 - Exercised - - - - $ - - Canceled/forfeited (745,000 ) $ 2 - (153,334 ) $ 2 - Outstanding, end of period 4,328,332 $ 2 3.03 4,098,332 $ 2 3.08 Options exercisable, end of period 4,328,332 $ 2 3.03 4,098,332 $ 2 3.08 Weighted average fair value of options granted $ 2 $ 1.98

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2022
Capital Stock
Capital Stock	Note 10 – Capital Stock Authorized: The Company has authorized 100,000,000 shares of common stock, par value $0.0001, and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001. Series A Preferred Stock: The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the “Stated Value”). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company’s common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on all such matters, regardless of the actual number of shares of Class A Preferred Stock then outstanding. There were 2,000 shares of Series A Preferred Stock issued and outstanding as of December 31, 2022 and 2021. Common Stock In December 2022, the Company issued 150,000 shares of its common stock to Quick Capital LLC with a value of $76,350 related to a loan amendment (Note 5). There were 13,439,789 and 13,289,789 shares of common stock issued and outstanding as of December 31, 2022 and 2021. Common Stock Purchase Warrants As of December 31, 2022 and 2021, the following common stock purchase warrants were outstanding: Warrants Weighted Average Exercise Price Outstanding – December 31, 2020 180,000 $ 1.00 Granted 115,000 (1) 1.00 Canceled/forfeited - - Exercised - - Outstanding – December 31, 2021 295,000 1.00 Granted - - Canceled/forfeited - - Exercised - - Outstanding – December 31, 2022 295,000 $ 1.00 (1) On June 15, 2021, the Company granted a convertible noteholder a warrant to purchase 115,000 shares of common stock at an exercise price of $1.00, subject to adjustments for full ratchet resets for dilutive issuances at lower prices. (See Note 5(2) above.)

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events
Subsequent Events	Not e 11 – Subsequent Events The Company has evaluated events for the period through the date of the issuance of these financial statements and determined that there are no additional events requiring disclosure.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
New Accounting Pronouncements	In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
Financial Statement Presentation:	Financial Statements:
Fiscal Year End:	Fiscal year end:
Use of Estimates:	Use of Estimates:
Cash Equivalents:	Cash Equivalents:
Research and Development Costs:	Research and Development Costs: Research and Development
Advertising and Marketing Costs:	Advertising and Marketing Costs:
Related Parties:	Related Parties:
Stock Based Compensation and Other Share-Based Payments:	Stock Based Compensation and Other Share-Based Payments: Compensation - Stock Compensation
Fair Value of Financial Instruments	ASC 820, Fair Value Measurements Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities as of December 31, 2022 and 2021: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of December 31, 2022: Liabilities Derivative liabilities $ - $ - $ 358,775 As of December 31, 2021: Liabilities Derivative liabilities $ - $ - $ 405,957
Warrants:	Warrants: Derivatives and Hedging
Income taxes:	Income taxes: Income Taxes
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Earnings Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The table below reflects the potentially dilutive securities outstanding during each reporting period: December 31, 2022 December 31, 2021 Research warrants at 3% of issued and outstanding shares 403,194 398,694 Convertible notes 460,000 564,719 Series A preferred shares 700 700 Stock options vested 4,328,332 4,098,332 Stock purchase warrants 295,000 295,000 Total 5,487,226 5,357,445

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
table below reflects the potentially dilutive securities at each reporting period	Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of December 31, 2022: Liabilities Derivative liabilities $ - $ - $ 358,775 As of December 31, 2021: Liabilities Derivative liabilities $ - $ - $ 405,957
table below reflects the potentially dilutive securities at each reporting period	December 31, 2022 December 31, 2021 Research warrants at 3% of issued and outstanding shares 403,194 398,694 Convertible notes 460,000 564,719 Series A preferred shares 700 700 Stock options vested 4,328,332 4,098,332 Stock purchase warrants 295,000 295,000 Total 5,487,226 5,357,445

Convertible Note Related Part_2

Convertible Note Related Party and Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Convertible Note Related Party and Derivative Liabilities
The carrying value of these convertible notes is as follows	December 31, 2022 December 31, 2021 Face value of certain convertible notes $ 25,000 $ 25,000 Convertible notes extinguish (25,000 ) - Carrying value $ - $ 25,000
Schedule of interest on the convertible note	For Years Ended December 31, 2022 2021 Interest on the convertible notes $ 1,424 $ 2,000
the derivative liability associated with the conversion	Balance at December 31, 2020 $ 61,682 Change in fair value 11,417 Balance at December 31, 2021 73,099 Change in fair value (73,099 ) Balance at December 31, 2022 $ 0
derivative liabilities were based upon the following management assumptions	Commitment Date December 31, 2021 September 27, 2022 Expected dividends 0 0 0 Expected volatility 101%-103 % 181%-182 % 101.56 % Expected term 0.92 - 1 year 0.67 - 0.74 year 0.00 year Risk free interest rate 1.33 % 1.06 % 2.22 %

Convertible Note and Derivati_2

Convertible Note and Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Convertible Note and Derivative Liabilities
carrying value of these convertible notes	December 31, 2022 December 31, 2021 Face value of certain convertible notes $ 80,000 $ 80,000 Less: unamortized discount - (541 ) Carrying value $ 80,000 $ 79,459
Interest expenses associated with the convertible notes	Years Ended December 31, 2022 2021 Amortization on debt discount $ 541 $ 35,823 Interest on the convertible notes 6,400 5,496 Total $ 6,941 $ 41,319
the fair value of the derivative liability associated with the conversion feature	Balance at December 31, 2020 $ 92,803 Change in fair value 64,687 Balance at December 31, 2021 157,490 Change in fair value (100,457 ) Balance at December 31, 2022 $ 57,033
the commitment and re-measurement dates	Commitment Date December 31, 2021 December 31, 2022 Expected dividends 0 0 0 Expected volatility 154%-173 % 203%-301 % 194.20%-201.98 % Expected term 2.10 years 1.08 - 1.22 years 1.08 - 1.22 years Risk free interest rate 1.42 - 1.65 % 0.39 % 4.41 %
Details of the valuation shares of common stock	December 7, 2022: Note Payable, original face value $ 115,000 Accrued interest and default penalty on default 71,300 Convertible Note Payable, amended (150,000 ) Debt discount, day one, amended convertible note payable 24,436 Derivative Liability associated with warrants (15,416 ) Change in Fair Value 31,030 Fair value of Common stock issued $ 76,350 Measurement date Dividend yield 0 % Expected volatility 114.69-209.74 % Risk-free interest rate 0.39%-3.79 % Expected life (years) 3 - 5 Stock Price $ 0.38 - 2.80 Exercise Price $ 0.40 - 2.00
The carrying value of the Quick Note is as follows	December 31, 2022 December 31, 2021 Face value of Quick Note $ 150,000 $ 115,000 Less: unamortized discount (21,753 ) (52,774 ) Carrying value $ 128,247 $ 62,226
Interest expenses associated with the conversion	Years ended December 31, 2022 2021 Amortization of debt discount $ 55,655 $ 62,226 Default interest 62,100 - Day one loss associated with derivative liability - 79,332 Interest on the convertible notes 4,973 5,016 Total $ 122,728 $ 146,574
the fair value of the derivative liability associated with the conversion feature is summarized as follows	Derivative liability associated with convertible note on commitment date $ 51,009 Derivative liability associated with warrants on commitment date 143,323 Change in fair value – convertible note (21,597 ) Change in fair value – warrants 2,633 Balance at December 31, 2021 175,368 Derivative liability associated with Note amendment – warrants (15,416 ) Change in fair value – convertible note (5,161 ) Change in fair value – warrants 146,951 Balance at December 31, 2022 $ 301,742
fair value at the commitment and re-measurement dates for the Company's derivative liabilities	Convertible note: Commitment Date December 31, 2021 December 31, 2022 Expected dividends 0 0 0 Expected volatility 307.10 % 215.70 % 119.70 % Expected term 1 years 0.45 years 0.45 years Risk free interest rate 0.18 % 0.43 % 4.37 % Warrants: Commitment Date December 31, 2021 December 31, 2022 Expected dividends 0 0 0 Expected volatility 201.70 % 200.90 % 219.10 % Expected term 5 years 4.45 years 4.45 years Risk free interest rate 0.65 % 0.82 % 4.27 %

Stock Plan (Tables)

Stock Plan (Tables)	12 Months Ended
	Dec. 31, 2022
Stock Plan
Summary of the activity for recognized compensation in respect of the above stock option compensation	Years ended December 31, 2023 2022 Research and development expenses $ 160,210 $ 223,985
Summary of the activity for the Company's stock options	December 31, 2022 December 31, 2021 Weighted Average Exercise Weighted Average Remaining Contractual Life Weighted Average Exercise Weighted Average Remaining Contractual Life Shares Price (in years) Shares Price (in years) Outstanding, beginning of period 4,098,332 $ 2 3.08 3,276,666 $ 1.98 3.28 Granted 975,000 2 - 975,000 $ 2 - Exercised - - - - $ - - Canceled/forfeited (745,000 ) $ 2 - (153,334 ) $ 2 - Outstanding, end of period 4,328,332 $ 2 3.03 4,098,332 $ 2 3.08 Options exercisable, end of period 4,328,332 $ 2 3.03 4,098,332 $ 2 3.08 Weighted average fair value of options granted $ 2 $ 1.98
Summary of the activity for compensation in respect of the above stock option compensationgeneral and administrative expenses	Years ended December 31, 2022 2021 General and administrative expenses $ 320,420 $ 435,570

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2022
Capital Stock
the following common stock purchase warrants were outstanding	Warrants Weighted Average Exercise Price Outstanding – December 31, 2020 180,000 $ 1.00 Granted 115,000 (1) 1.00 Canceled/forfeited - - Exercised - - Outstanding – December 31, 2021 295,000 1.00 Granted - - Canceled/forfeited - - Exercised - - Outstanding – December 31, 2022 295,000 $ 1.00

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Level 1 [Member]
Liabilities
Derivative liabilities	$ 0	$ 0
Level 2 [Member]
Liabilities
Derivative liabilities	0	0
Level 3 [Member]
Liabilities
Derivative liabilities	$ 358,775	$ 405,957

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Potentially dilutive securities net loss per share	5,487,226	5,357,445
Series A Preferred Shares [Member]
Potentially dilutive securities net loss per share	700	700
Research Warrants at 3% of issued and outstanding shares [Member]
Potentially dilutive securities net loss per share	403,194	398,694
Stock purchase warrants [Member]
Potentially dilutive securities net loss per share	295,000	295,000
Stock options vested [Member]
Potentially dilutive securities net loss per share	4,328,332	4,098,332
Convertible Note [Member]
Potentially dilutive securities net loss per share	460,000	564,719

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies
Research and development costs	$ 194,406	$ 258,297
Advertising or marketing costs	$ 0	$ 0

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Going Concern
Proceeds from loan	$ 100,000	$ 72,500

Convertible Note Related Part_3

Convertible Note Related Party and Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Carrying value	$ 0	$ 25,000
Related Party Debt [Member]
Carrying value	0	25,000
Face value of certain convertible notes	25,000	0
Convertible notes extinguish	$ (25,000)	$ 25,000

Convertible Note Related Part_4

Convertible Note Related Party and Derivative Liabilities (Details 1) - USD ($)	12 Months Ended		24 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022
Interest on the convertible notes	$ 4,973	$ 5,016
Related Party Debt [Member]
Interest on the convertible notes	$ 1,424		$ 2,000

Convertible Note Related Part_5

Convertible Note Related Party and Derivative Liabilities (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Changes in Fair Value	$ (100,457)	$ 64,687
Derivative Liabilities [Member]
Beganing balance	73,099	61,682
Changes in Fair Value	(73,099)	11,417
Ending balance	$ 0	$ 73,099

Convertible Note Related Part_6

Convertible Note Related Party and Derivative Liabilities (Details 3)	1 Months Ended	12 Months Ended
	Sep. 27, 2022	Dec. 31, 2022	Dec. 31, 2021
Minimum [Member]
Expected term		1 year 29 days	1 year 29 days
Maximum [Member]
Expected term		1 year 2 months 19 days	1 year 2 months 19 days
Commitment Date [Member]
Expected term		1 year
Related Party Debt [Member]
Expected dividends	0%		0%
Risk free interest rate	2.22%		1.06%
Expected volatility	101.56%
Expected term	0 years
Related Party Debt [Member] | Minimum [Member]
Expected volatility			181%
Expected term			67 years
Related Party Debt [Member] | Maximum [Member]
Expected volatility			182%
Expected term			74 years
Related Party Debt [Member] | Commitment Date [Member]
Expected dividends	0%
Risk free interest rate	1.33%
Related Party Debt [Member] | Commitment Date [Member] | Minimum [Member]
Expected volatility	101%
Expected term	11 months 1 day
Related Party Debt [Member] | Commitment Date [Member] | Maximum [Member]
Expected volatility	103%
Expected term	1 year

Convertible Note Related Part_7

Convertible Note Related Party and Derivative Liabilities (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Sep. 27, 2022	Sep. 27, 2017	Sep. 01, 2016	Dec. 31, 2022	Dec. 31, 2021
Proceeds from convertible notes				$ 0	$ 100,000
Cubesquare Llc [Member]
Convertible debenture agreement		$ 15,000	$ 10,000
Ownership percentage			25%	8%
Interest rate per annum		8%	8%	8%
Conversion, description		any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare	(i) $0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender
Accounts payable and accrued liabilities related party				$ 0	$ 9,449
Principal amount - related party convertible note modified to 6% promissory note	$ 35,873
Aggregate principal amount - related party convertible note modified to 6% promissory note	25,000
Accrued interest payable - related party convertible note modified to 6% promissory note	$ 10,873

Convertible Note and Derivati_3

Convertible Note and Derivative Liabilities (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Carrying value	$ 0	$ 25,000
Derivative Liabilities [Member]
Face value of certain convertible notes	80,000	80,000
Less: unamortized discount	0	(541)
Carrying value	$ 80,000	$ 79,459

Convertible Note and Derivati_4

Convertible Note and Derivative Liabilities (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total	$ 122,728	$ 146,574
Warrants [Member]
Interest on the convertible notes	6,400	5,496
Amortization on debt discount	541	35,823
Total	$ 6,941	$ 41,319

Convertible Note and Derivati_5

Convertible Note and Derivative Liabilities (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Convertible Note and Derivative Liabilities
Balance at beginning	$ 157,490	$ 92,803
Change in fair value	(100,457)	64,687
Balance at ending	$ 57,033	$ 157,490

Convertible Note and Derivati_6

Convertible Note and Derivative Liabilities (Details 3)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Expected dividend	0%	0%
Risk free interest	4.41%	0.39%
Minimum [Member]
Expected volatility	194.20%	203%
Expected term	1 year 29 days	1 year 29 days
Maximum [Member]
Expected volatility	201.98%	301%
Expected term	1 year 2 months 19 days	1 year 2 months 19 days
Commitment Dates Minimum [Member]
Risk free interest	1.42%
Expected volatility	154%
Commitment Dates Maximum [Member]
Risk free interest	1.65%
Expected volatility	173%
Commitment Date [Member]
Expected dividend	0%
Risk free interest	0.18%
Expected volatility	307.10%
Expected term	2 years 1 month 6 days
Expected term	1 year

Convertible Note and Derivati_7

Convertible Note and Derivative Liabilities (Details 4)	Dec. 07, 2022 USD ($)
Convertible Note and Derivative Liabilities
Note Payable, original face value	$ 115,000
Accrued interest and default penalty on default	71,300
Convertible Note Payable, amended	(150,000)
Change in Fair Value 1	31,030
Debt discount, day one, amended convertible note payable	24,436
Derivative Liability associated with warrants	(15,416)
Fair value of Common stock issued	$ 76,350

Convertible Note and Derivati_8

Convertible Note and Derivative Liabilities (Details 5) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Carrying value	$ 0	$ 25,000
Quick Note [Member]
Face value of Quick Note	150,000	115,000
Less: unamortized discount	(21,753)	(52,774)
Carrying value	$ 128,247	$ 62,226

Convertible Note and Derivati_9

Convertible Note and Derivative Liabilities (Details 6) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Convertible Note and Derivative Liabilities
Amortization of debt discount	$ 55,655	$ 62,226
Default interest	62,100	0
Day one loss associated with derivative liability	0	79,332
Interest on the convertible notes	4,973	5,016
Total	$ 122,728	$ 146,574

Convertible Note and Derivat_10

Convertible Note and Derivative Liabilities (Details 7) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance at ending	$ 57,033	$ 157,490
Commitment [Member] Warrants [Member] | Convertible Note June [Member]
Derivative liability associated with convertible note on commitment date		51,009
Derivative liability associated with warrants on commitment date		143,323
Derivative liability associated with Note amendment - warrants	(15,416)
Change in fair value - convertible note	(5,161)	(21,597)
Change in fair value - warrants	146,951	2,633
Balance at ending	$ 301,742	$ 175,368

Convertible Note and Derivat_11

Convertible Note and Derivative Liabilities (Details 8)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Expected dividend	0%	0%
Risk free interest	4.41%	0.39%
Commitment Date [Member]
Expected dividend	0%
Risk free interest	0.18%
Expected volatility	307.10%
Expected term	1 year
Commitment [Member] Warrants [Member]
Expected dividend	0%	0%
Risk free interest	4.27%	0.82%
Expected volatility	219.10%	200.90%
Expected term	4 years 5 months 12 days	4 years 5 months 12 days
Commitment And Warrants [Member]
Expected dividend	0%
Risk free interest	0.65%
Expected volatility	201.70%	2.90%
Expected term	5 years
Convertible Note [Member]
Expected dividend	0%	0%
Risk free interest	4.37%	0.43%
Expected volatility	119.70%	215.70%
Expected term	5 months 12 days	5 months 12 days

Convertible Note and Derivat_12

Convertible Note and Derivative Liabilities (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Jun. 15, 2021	Feb. 19, 2020	Dec. 31, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Proceeds from convertible notes				$ 0	$ 100,000
Accrued interest				124,200
Accrued interest outstanding				186,300
Restricted common stock valued				76,350
Issuance of common stock shares				150,000
Derivative Liabilities [Member]
Proceeds from convertible notes	$ 100,000
Interest rate per annum		8%	8%
Conversion description		we issued and sold in a private offering an 8% convertible note in the principal amount of $10,000. The note is due on February 19, 2022 and is convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; or (c) such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance	convertible into shares of our common stock at a conversion price for each share of common stock equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) so long as lower than (a) or (b), such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00
Accounts payable and accrued liabilities related party				19,269	12,869
Derivative liability convertible notes				80,000
Derivative liabilities				$ 0	$ 73,099	$ 61,682
Principal amount	115,000	$ 10,000	$ 70,000
Liquidated damages payment, daily	$ 2,000

Unsecured ShortTerm Advance fro

Unsecured ShortTerm Advance from Third Party (Details Narrative) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Unsecured ShortTerm Advance from Third Party (Details Narrative)
Unsecured short-term advances	$ 100,000	$ 100,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 27, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 27, 2017	Sep. 01, 2016
Due to related party		$ 15,234	$ 10,674
Cubesquare Llc [Member]
Due to related party		$ 50,000		$ 10,000
Interest percentage		8%				8%	8%
Ownership percentage		25%
Interest expense		$ 4,000
Accrued interest payable	$ 10,873
Aggregate principal amount - related party	25,000
Principal amount - related party convertible note	$ 35,873
Accounts payable and accrued liabilities		10,674
Ido Merfeld [Member]
Due to related party		50,000		$ 21,000	$ 1,169
Accounts payable and accrued liabilities		1,169
Advances amount		71,000
Jonah Meer [Member]
Due to related party		135,000	70,000
Accounts payable and accrued liabilities		26,268	16,900
Additional advances received		72,500
Advances amount		277,500	205,000
Payment of advances		$ 900	$ 11,575

Intellectual Property License_2

Intellectual Property License Agreement and Sponsored Research Agreement (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Intellectual Property License Agreement and Sponsored Research Agreement
License fee	$ 25,000	$ 25,000
Royalty expense	500,000
Licence expense	$ 25,000	$ 25,000
Royalty percentage of net sales	2%

Stock Plan (Details)

Stock Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Research and Development Expense [Member]
Stock option compensation allocated expenses	$ 160,210	$ 223,985
General and Administrative Expense [Member]
Stock option compensation allocated expenses	$ 320,420	$ 435,570

Stock Plan (Details 1)

Stock Plan (Details 1) - Measurement Date [Member] - Stock Option [Member]	12 Months Ended
	Dec. 31, 2022 $ / shares
Dividend yield	0%
Exercise Price, Minimum	$ 0.40
Exercise Price, Maximum	$ 2
Minimum [Member]
Expected volatility	114.69%
Risk-free interest rate	0.39%
Expected life (years)	3 years
Stock Price	$ 0.38
Maximum [Member]
Expected volatility	209.74%
Risk-free interest rate	3.79%
Expected life (years)	5 years
Stock Price	$ 2.80

Stock Plan (Details 2)

Stock Plan (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock Plan
Shares Outstanding, beginning of period	4,098,332	3,276,666
Shares, Granted	975,000	975,000
Shares Outstanding, end of period	4,328,332	4,098,332
Shares Options exercisable, end of period	4,328,332	4,098,332
Weighted Average Shares Exercise Price, Outstanding, beginning of period	$ 2	$ 1.98
Weighted Average Shares Exercise Price, Granted	2	2
Weighted Average Shares Exercise Price, Exercised	0	0
Weighted Average Exercise Price, Canceled/forfeited	2	2
Weighted Average Shares Exercise Price, Outstanding, Ending of period	2	2
Weighted Average Exercise Price, Weighted average fair value of options granted	$ 2	$ 1.98
Outstanding, Weighted Average Remaining Contractual Life	3 years 29 days	3 years 3 months 10 days
Options exercisable, Weighted Average Remaining Contractual Life	3 years 10 days	3 years 29 days
Outstanding, Weighted Average Remaining Contractual Life	3 years 10 days	3 years 29 days

Stock Plan (Details Narrative)

Stock Plan (Details Narrative) - USD ($)								1 Months Ended							12 Months Ended
	Dec. 04, 2022	Aug. 15, 2022	Feb. 10, 2021	Dec. 10, 2020	Feb. 10, 2020	Dec. 10, 2019	Dec. 10, 2018	Dec. 22, 2022	Dec. 17, 2022	Nov. 15, 2022	Jul. 01, 2022	Apr. 16, 2022	Dec. 22, 2021	Jun. 25, 2019	Dec. 31, 2022	Jan. 31, 2021	Jul. 15, 2020
Stock Options Granted To Employees [Member]
Granted an option to purchase of common stock		6,666		100,000				325,000	66,668	28,332	33,334	10,000	325,000
Weighted average excercise price				$ 2				$ 2					$ 2
Description of services agreement				On December 10, 2020, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share and are immediately exercisable		On December 10, 2019, the Board awarded an employee, the following three-year stock options under the Plan: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2021 at an exercise price of $2.00 per share, provided the employee is providing services to the Company at the time of exercise. On March 23, 2020, the Company accelerated the vesting provision to provide for the immediate vesting of such options. Such options expired on March 23, 2023.	On December 10, 2018, the Board awarded an employee the following three-year stock options under the Plan: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, provided the employee is providing services to the Company at the time of exercise. On March 23, 2020, the Company accelerated the vesting provision to provide for the immediate vesting of such options. 33,333 of such shares subject to the option were forfeited unexercised on December 10, 2021. The remaining option expired on March 23, 2023.						On December 22, 2021, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share and are immediately exercisable
Unrecognized compensation															$ 0
Stock Options Granted To Science Advisor And Business Advisors [Member]
Granted an option to purchase of common stock					50,000								325,000
Weighted average excercise price				$ 2	$ 2								$ 2
Expiry date			February 10, 2024		February 10, 2023
Unvested options			25,000													25,000	25,000
Share exercisable					25,000
Stock Options Granted To Officers [Member]
Granted an option to purchase of common stock	600,000			325,000				325,000					325,000
Weighted average excercise price				$ 2				$ 2					$ 2
Description of services agreement														On June 25, 2019, the Company appointed John N. Bonfiglio, PhD as its chief operating officer, effective July 1, 2019. As compensation, Dr. Bonfiglio was granted a three-year stock option to purchase 100,000 shares of common stock at an exercise price of $2.00 per share, 50,000 of which shares vested upon grant and 25,000 shares vested on each of July 1, 2020 and July 1, 2021, provided Dr. Bonfiglio was in the employ of the Company on such dates. Mr. Bonfiglio was terminated as chief operating officer as of November 30, 2019. Accordingly, all unvested stock options terminated on such date. In January 2021, 50,000 vested options were forfeited.

Capital Stock (Details)

Capital Stock (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Capital Stock
Warrants Outstanding beganing	295,000	180,000
Warrants Granted	0	115,000
Warrants Canceled/forfeited	0	0
Warrants exercised	0	0
Warrants Outstanding Ending	295,000	295,000
Weighted Average Exercise Price Outstanding beganing	$ 1	$ 1
Weighted Average Exercise Price Granted	0	1
Weighted Average Exercise Price Canceled/Forfeited	0	0
Weighted Average Exercise Price Exercised	0	0
Weighted Average Exercise Price Outstanding Ending	$ 1	$ 1

Capital Stock (Details Narrativ

Capital Stock (Details Narrative) - USD ($)				1 Months Ended			12 Months Ended
	Jun. 06, 2021	Aug. 08, 2019	Jul. 10, 2019	Jun. 15, 2021	Sep. 18, 2019	Jan. 23, 2018	Dec. 31, 2022	Dec. 31, 2021
Common Stock, Shares Authorized							100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share							$ 0.0001	$ 0.0001
Warrants to purchase common stock	115,000
Common stock exercise price per share				$ 1
Common Stock, Shares Issued							13,439,789	13,289,789
Common Stock, value							$ 1,344	$ 1,329
Common Stock, Shares, Outstanding							13,439,789	13,289,789
Number of common shares issued for warrants		50,000	37,500	115,000	25,000	10,000
Preferred Stock, Shares Authorized							10,000	10,000
Preferred Stock, Par or Stated Value Per Share							$ 0.001	$ 0.001
Preferred Stock, Shares Issued							2,000	2,000
Preferred Stock, Shares Outstanding							2,000	2,000
Quick Capital LLC [Member]
Common Stock, Shares Issued							150,000
Common Stock, value							$ 76,350
Series A, Preferred Stock
Preferred Stock, Shares Authorized							10,000	10,000
Preferred Stock, Par or Stated Value Per Share							$ 0.001	$ 0.001
Preferred Stock, Shares Issued							2,000	2,000
Preferred Stock, Shares Outstanding							2,000	2,000
Preferred Stock price per share							$ 1
Preferred stock share percentage per annum							4%